SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

NovoCure Ltd. – ‘8-K’ for 5/2/24

On:  Thursday, 5/2/24, at 7:01am ET   ·   For:  5/2/24   ·   Accession #:  1645113-24-14   ·   File #:  1-37565

Previous ‘8-K’:  ‘8-K’ on / for 3/27/24   ·   Latest ‘8-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/02/24  NovoCure Ltd.                     8-K:2,9     5/02/24   11:263K

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    110K 
 6: R1          Document and Entity Information Document            HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
11: XML         XBRL Instance -- nvcr-20240502_htm                   XML     13K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- nvcr-20240502_lab                     XML     62K 
 5: EX-101.PRE  XBRL Presentations -- nvcr-20240502_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- nvcr-20240502                         XSD     10K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
10: ZIP         XBRL Zipped Folder -- 0001645113-24-000014-xbrl      Zip     24K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C: 
  nvcr-20240502  
 i 0001645113 i false00016451132024-03-012024-05-03


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  i 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 i May 2, 2024
Date of Report (date of earliest event reported)

 i NovoCure Limited
(Exact name of registrant as specified in its charter)
 i Jersey
 i 001-37565
 i 98-1057807
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 i No. 4 The Forum, Grenville Street
 i St. Helier
 i Jersey
 i JE2 4UF
(Address of Principal Executive Offices)
(Zip Code)
+ i 44 (0) 15  i 3475 6700
Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 i  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Ordinary Shares, no par value i NVCR i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o




Item 2.02     Results of Operations and Financial Condition.

On May 2, 2024, the Company issued a press release announcing certain financial results for the quarter ended
March 31, 2024. A copy of the press release is attached as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited
(Registrant)

Date: May 2, 2024


By: /s/ Ashley Cordova  
Name: Ashley Cordova
Title: Chief Financial Officer


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:5/2/24None on these Dates
3/31/24
 List all Filings 
Top
Filing Submission 0001645113-24-000014   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 6:14:07.1pm ET